Showing results (381-390 of 793) with videos related to
Sort By:
Pageof 80
Blood|May 23, 2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myelomaAjai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.Nature Communications|April 25, 2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosisBenjamin G Barwick, Paola Neri, Nizar J Bahlis, et al.Blood|April 14, 2005
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.Journal of Primary Care & Community Health|July 25, 2024
Writing Groups for Healthcare Professionals in Academic MedicineIvana T Croghan, Shaji Kumar, Sagar B Dugani, et al.Mayo Clinic Proceedings|February 5, 2019
Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015Robert A Kyle, Dirk R Larson, Paul J Kurtin, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TransplantationSteven Z Pavletic, Shaji Kumar, Mohamad Mohty, et al.European Journal of Haematology|May 8, 2013
Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myelomaAlexandra J Greenberg, Margot Cousin, Shaji Kumar, et al.Leukemia & Lymphoma|November 12, 2013
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesTariq I Mughal, Saulius Girnius, Steven T Rosen, et al.Pageof 80